SLC5A2 and hyperinsulinism: In summary, we show that early cardioprotective effects of empagliflozin treatment in db/db mice cannot be explained by well-known pleiotropic effects of SGLT-2 inhibitors such as reduction of body weight or improved hyperinsulinemia.